Get the Stockscreener App
1.30
3.70%
-0.05
After Hours:
1.33
0.03
+2.31%
Redhill Biopharma Ltd Adr stock is traded at $1.30, with a volume of 94,925.
It is down -3.70% in the last 24 hours and down -40.09% over the past month.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
See More
Previous Close:
$1.35
Open:
$1.37
24h Volume:
94,925
Relative Volume:
0.07
Market Cap:
$4.33M
Revenue:
$35.75M
Net Income/Loss:
$11.57M
P/E Ratio:
-0.3415
EPS:
-3.8069
Net Cash Flow:
$-26.25M
1W Performance:
-20.73%
1M Performance:
-40.09%
6M Performance:
-41.04%
1Y Performance:
-84.22%
1-Day Range:
$1.30
$1.38
1-Week Range:
$1.30
$1.67
52-Week Range:
$1.06
$8.75
Redhill Biopharma Ltd Adr Stock (RDHL) Company Profile
Compare RDHL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
1.30 | 4.50M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Redhill Biopharma Ltd Adr Stock (RDHL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-31-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-11-20 | Initiated | BTIG Research | Buy |
| Jul-12-19 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-12-19 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Jan-26-18 | Initiated | Nomura | Buy |
| Oct-06-17 | Initiated | Seaport Global Securities | Buy |
| Oct-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-17 | Reiterated | FBR & Co. | Outperform |
| Jul-27-16 | Reiterated | FBR Capital | Outperform |
| Sep-29-15 | Initiated | Nomura | Buy |
| Jul-29-15 | Reiterated | ROTH Capital | Buy |
| Jun-17-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-15 | Reiterated | ROTH Capital | Buy |
View All
Redhill Biopharma Ltd Adr Stock (RDHL) Latest News
RedHill Biopharma to appeal Nasdaq compliance notice - Investing.com
RedHill Biopharma to appeal Nasdaq compliance notice By Investing.com - Investing.com South Africa
RDHL appeals Nasdaq notice; 180-day extension possible - Stock Titan
RedHill Biopharma Receives Nasdaq Staff Determination Notification - Benzinga
RedHill Biopharma Receives Nasdaq Staff Determination Notification - Barchart.com
RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal - PR Newswire
CID Holdco Inc (DAIC): What Does Valuation Ratios Tell Us? - fostersleader.com
Lixte Biotechnology Holdings Inc (LIXT): What Technical Indicators Show - fostersleader.com
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia® - Sahm
RedHill Biopharma stock surges after court upholds $10M judgment - Investing.com
RedHill Biopharma stock surges after court upholds $10M judgment By Investing.com - Investing.com South Africa
Is RDHL Poised for Rebound? Analyzing Financial Moves - StocksToTrade
RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo - Sahm
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights - Placera.se
RedHill Received Talicia® Licensing Payments Totaling $1.1 Million - PR Newswire
RedHill Biopharma receives Nasdaq extension to regain compliance by October - Investing.com South Africa
Redhill Biopharma stock soars after FDA provides positive pathway for Crohn’s drug - Investing.com India
RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress - Finansavisen
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - PR Newswire
Redhill Biopharma stock hits 52-week low at $1.72 amid market challenges - Investing.com India
Redhill Biopharma stock hits 52-week low at $2.47 amid steep annual decline - Investing.com
RedHill Biopharma targets UK approval for H. pylori therapy - Investing.com
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline - Investing.com
Hyloris secures global rights to RedHill's RHB-102 - Investing.com
RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published - PR Newswire
Talicia® Launched in the United Arab Emirates - PR Newswire
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire
RedHill Biopharma finalizes agreement to enhance cash position - Investing.com
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042 - PR Newswire
Balancing Acidity: Exploring the Proton Pump Inhibitors Market - openPR.com
symbol__ Stock Quote Price and Forecast - CNN
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. - Barchart.com
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds - Barchart.com
Phil and RedHill Biopharma Partner to Increase Access to Talicia® - Business Wire
Why Beyond Meat Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket - Benzinga
RedHill’s Aemcolo® Granted FDA QIDP 5-Year Exclusivity Extension - BioSpace
Extremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment - PR Newswire UK
RedHill presents New Talicia® and Movantik® data analyses at ACG 2022 - EurekAlert!
RedHill Biopharma and Gaelan Medical Enter Into License Agreement for Talicia® for the United Arab Emirates - PR Newswire
RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021 - BioSpace
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D - PR Newswire
RedHill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to Over 40 Million Additional Americans - Stock Titan
RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults - GlobeNewswire
RedHill Biopharma: TALICIA Launch For H. Pylori In Sight - Investing.com
RedHill Biopharma's Drug Pipeline May Merit Substantial Upside, And Potential Catalysts Are On The Horizon - Seeking Alpha
REDHILL BIOPHAR/S ADR (NASDAQ:RDHL) had its Buy rating reiterated by HC Wainwright - marketexclusive.com
Technical Analysis of RedHill Biopharma Ltd. Sponsored ADR (NASDAQ:RDHL) - TradingView
RDHL Stock Price and Chart — NASDAQ:RDHL - TradingView
S&W Seed Company (SANW): How Does It Stack Up Against Its Peers? - Insider Monkey
Redhill Biopharma (RDHL) Stock Price, News & Analysis - MarketBeat
Redhill Biopharma Ltd Adr Stock (RDHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.18%
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):